Michael Juchum

Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy‐Resistant L858R/T790M/C797S Mutant

Marcel Günther, Michael Juchum, Gerhard Kelter et al. · Angewandte Chemie International Edition · 2016 · 102 citations

Drug Targeting, Oncology, Novel Therapy +15

Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site

Marcel Günther, Jonas Lategahn, Michael Juchum et al. · Journal of Medicinal Chemistry · 2017 · 102 citations · Full text

Drug Target, Both Hydrophobic Regions, Chemical Biology +21

Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping

Michael Juchum, Marcel Günther, Eva Döring et al. · Journal of Medicinal Chemistry · 2017 · 82 citations · Full text

Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration

Bent Pfaffenrot, Philip Klövekorn, Michael Juchum et al. · European Journal of Medicinal Chemistry · 2021 · 22 citations · Full text

Medicinal Chemistry, Natural Sciences, Drug Discovery +9

From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4)

Philip Klövekorn, Bent Pfaffenrot, Michael Juchum et al. · European Journal of Medicinal Chemistry · 2020 · 15 citations · Full text

New Braf-inhibitor-template-derived, Medicinal Chemistry, Drug Target +11